No headlines found.
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
Globe Newswire (Wed, 19-Aug 4:05 PM ET)
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Wed, 19-Aug 4:01 PM ET)
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
Globe Newswire (Thu, 6-Aug 7:00 AM ET)
Globe Newswire (Mon, 3-Aug 7:00 AM ET)
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
Globe Newswire (Thu, 9-Jul 7:00 AM ET)
Globe Newswire (Mon, 6-Jul 7:00 AM ET)
Opus Genetics Added to the Russell 3000, Russell 2000 and Russell Microcap Indexes
Globe Newswire (Fri, 26-Jun 9:15 AM ET)
Globe Newswire (Tue, 16-Jun 4:05 PM ET)
Globe Newswire (Tue, 2-Jun 7:00 AM ET)
Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference
Globe Newswire (Wed, 27-May 8:00 AM ET)
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
Opus Genetics trades on the NASDAQ stock market under the symbol IRD.
As of August 19, 2026, IRD stock price climbed to $4.07 with 704,604 million shares trading.
IRD has a beta of 0.78, meaning it tends to be less sensitive to market movements. IRD has a correlation of 0.02 to the broad based SPY ETF.
IRD has a market cap of $338.61 million. This is considered a Small Cap stock.
Last quarter Opus Genetics reported $755,000 in Revenue and -$.14 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.02.
The top ETF exchange traded funds that IRD belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
IRD has outperformed the market in the last year with a price return of +253.9% while the SPY ETF gained +20.7%. However, in the short term, IRD had mixed performance relative to the market. It has underperformed in the last 3 months, returning -8.3% vs +4.4% return in SPY. But in the last 2 weeks, IRD shares have fared better than the market returning +9.7% compared to SPY -0.3%.
IRD support price is $3.52 and resistance is $3.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IRD shares will trade within this expected range on the day.
